Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07099001 · ClinicalTrials.gov registry record · NA

Establishing Clinical Utility Evidence for a Novel Alzheimer's Disease Blood-Based Biomarker Assay

A NA study of Cognitive Decline and Alzheimer Disease (AD), sponsored by Qure Healthcare.

Completed
Registry status
NA
Development phase
178
Enrollment target
1
Study location

NCT07099001: Completed NA study of Cognitive Decline and Alzheimer Disease (AD), sponsored by Qure Healthcare.

NCT07099001 is a NA study of Cognitive Decline and Alzheimer Disease (AD) that has completed, run by Qure Healthcare. The registered enrollment target is 178 participants, below the 1,147-participant average among 61 other Cognitive Decline trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07099001, a NA study of Cognitive Decline and Alzheimer Disease (AD), has completed, sponsored by Qure Healthcare.

COMPLETED
Registry status
NA
Development phase
178 participants
Enrollment target
1
Study location

Study Summary

This is a national-level research study of neurologists and dementia specialists. The purpose of this study is to assess the clinical evaluation and management recommendations made by practicing providers for patient simulations with symptoms of cognitive decline.

Primary Outcome

Difference-in-differences regression analysis between the control and the intervention groups' diagnosis and treatment of symptoms of cognitive decline, as measured by the participants' diagnostic and treatment case scores. In each QURE case, every participants' care recommendations are evaluated against evidence-based care scoring criteria, which can range from 0% to 100% (with higher percentages indicating better outcomes).

Interventions

  • OTHER Educational materials on the Alzheimer's disease assay
  • OTHER Alzheimer's disease assay results

Study Locations (1)

Missouri

  • QURE Healthcare - St Louis

Trial Details

FieldValue
Enrollment Target 178 participants
Start Date 2025-08-08
Est. Completion 2025-12-31
Phase NA
Qure Healthcare

21 total trials

What the finished NCT07099001 record still lists

NCT07099001 is an interventional study that assigns participants to a tested intervention. The registered 178 participants enrollment target is mid-sized for trials with a published cap, below the 1,147-participant average among 61 other Cognitive Decline trials with a reported enrollment target (84% lower).

The record links to 2 conditions, with Cognitive Decline appearing as the primary indexed condition, and to 2 interventions - of which Educational materials on the Alzheimer's disease assay is the first listed.

NCT07099001 reports a single indexed study location in Missouri.

Frequently Asked Questions

What is clinical trial NCT07099001 about?

NCT07099001 is a clinical study titled "Establishing Clinical Utility Evidence for a Novel Alzheimer's Disease Blood-Based Biomarker Assay". This is a national-level research study of neurologists and dementia specialists. The purpose of this study is to assess the clinical evaluation and management recommendations made by practicing providers for patient simulations with symptoms of cognitive decline.

What is the current status of trial NCT07099001?

This trial is currently completed. It is a NA study. The enrollment target is 178 participants. The study started on 2025-08-08. Estimated completion is 2025-12-31.

What conditions does trial NCT07099001 study?

This clinical trial studies the following conditions: Cognitive Decline, Alzheimer Disease (AD).

What interventions are being tested in trial NCT07099001?

The interventions under investigation include: Educational materials on the Alzheimer's disease assay (OTHER), Alzheimer's disease assay results (OTHER).

Who is sponsoring clinical trial NCT07099001?

This trial is sponsored by Qure Healthcare, which has 21 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07099001 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cognitive Decline

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07099001's enrollment target sits among peer trials

178 28th of 61 higher than 34 of 61 other Cognitive Decline trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cognitive Decline trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03642002 · 178 participants · NA

    The Effects of Music Therapy on Adult Patients Requiring Mechanical Ventilation in the ICU

  • NCT04227847 · 178 participants · Phase 1

    A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

  • NCT04855214 · 178 participants

    Evaluating the Experience of Upper Limb Prosthesis Use

  • NCT05391126 · 178 participants · NA

    GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07099001, the US trial registry maintained by the National Library of Medicine. NCT07099001 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.